Abstract tion was zimelidine--100 milligrams twice daily, methyprylon, oxazepam, and tetracycline. Tissues received after autopsy were: blood, urine, liver, bile, and brain.
Introduction
In recent years, the search for the "perfect" antidepressant has led to the introduction of many new drugs. Recently, in the author's laboratory, a case involving the use of zimelidine was encountered.
Zimelidine, marketed as Zelmid by Astra Pharmaceuticals Ltd., is a new antidepressant which is presently used only experimentally in Canada but which has been available in Europe for several years. Zimelidine (Figure 1 ), a bicyclic derivative of the antihistamine pheniramine is structurally unrelated to the tricyclic and tetracyclic antidepressants. It is a relatively specific inhibitor of the reuptake of serotonin in central neurons (1) .
Zimelidine, in daily doses of 150-300 mg, is completely absorbed from the gastrointestinal tract. It undergoes extensive "first-pass metabolism" in the liver to the demethylated metabolite norzimelidine ( Figure 1 ) (2) . Norzimelidine may be a more potent serotonin uptake blocker than zimelidine (1, 3) .
Case History
A 30-year-old female who was receiving psychiatric care died as a result of a self-inflicted gunshot wound. Her known medica-9 Presented at the Society sf Forensic Toxicologists meeting in Detroit in October, t 983.
Extraction
The optimum extraction (60%) of zimelidine and its metabolite was achieved using n-butyl chloride. Blood standards were spiked with zimelidine and norzimelidine in concentrations ranging from 0.10 to 1.0 mg/L. To a 2.5 mL blood sample, 0.1 mL of the internal standard (25 mg/L CPP-235) was added and the sample basified with 0.1 mL concentrated NH,OH prior to extraction with 10 mL n-butyl chloride. The samples were shaken for 5 min and then centrifuged. The n-butyl chloride extract was then back-extracted with 1.0 mL 0.1 N H2SO,. Use of a stronger acid at this step resulted in a significant loss of norzimelidine. The organic layer containing the methyprylon was evaporated and reconstituted in ethanol for quantification. The aqueous acid layer was made basic with 0.5 mL 0.45N NaOH and reextracted with n-butyl chloride. After shaking and centrifugation the organic layer was removed and evaporated. The sample was reconstituted in 50/zL ethanol and 1 #L injected on the gas chromatograph. In addition to zimelidine and norzimelidine, this fraction was also used for quantification of diphenhydramine using promethazine as the internal standard.
A similar extraction was performed with 2.5 mL urine, 2.5 mL liver/water homogenate (1/1), 2.5 mL brain/water homogenate (1/i), and 2.5 mL bile.
To determine total bile zimelidine and norzimelidine concentrations, 2.5 mL bile and 0.1 mL CPP-235 were hydrolyzed with 2.5 mL 1 .ON H2SO, in a pressure cooker for 20 minutes. Spiked aqueous standards were treated similarly. The filtered hydrolysates were extracted with 10 mL n-butyl chloride. The aqueous fractions were basified with 1.0 mL 4N NaOH and extracted with 10 mL n-butyl chloride. After centrifugation the organic layer was removed and evaporated.
Instrumental Data
Gas chromatography was performed on an HP 5880A instrument with a nitrogen/phosphorus detector. A 15-m DB-1 fused silica capillary column was programmed from 160~ to 280~ increasing at 8~ per minute. The helium carrier gas flow was 2 m / / m i n . Retention times for diphenhydramine, zimelidine, norzimelidine, promethazine, and CPP-235 were 4.13, 7.55, 7.73, 8.05, and 9.32 min, respectively. A typical gas chromatogram of a blood extract is shown in Figure 2 .
Mass spectra were obtained on a 4500 Finnigan electron impact mass spectrometer. The mass spectrum of zimelidine has a base peak of 58 and a molecular ion of 316. The bromine isotope cluster accounts for the peak at 318 (Figure 3 ). Norzimelidine has a base peak of 147 and a molecular ion of ]02 (Figure 4 ).
R e s u l t s a n d D i s c u s s i o n s
The drugs found in this case in addition to zimelidine and norzimelidine were diphenhydramine and methyprylon (Table Reported therapeutic norzimelidine levels are 2 to 4 times those of zimelidine (4) (5) (6) (7) (8) (9) , which is consistent with this case. However, in the liver the ratio of norzimelidine to zimelidine was 1 to 3. This contrasts to a 4 to 1 ratio found in the liver of a drowning victim whose blood zimelidine and norzimelidine concentrations were 0.3 and 0.9 m g / L respectively (11) .
Norzimelidine was excreted more extensively in the urine than was zimelidine. Blood and brain concentrations were of the same order.
The concentration of non-conjugated norzimelidine in the bile was 3.7 times that of zimelidine. This compares to a 3 fold difference found in the drowning victim reported previously (11) . In this case, the ratio of conjugated to free in bile was 2 to 1 for both zimelidine and norzimelidine.
This paper has reported zimelidine and norzimelidine levels in a suicide victim. It must be emphasized, however, that in this case death was not due to an overdose but normal therapeutic concentrations have been exceeded. --
